RxDoctor Payments DataLook up a doctor →

Jamie Weisman, MD

Dermatology · Atlanta, GANPI 1033131610

Payments from drug & device makers

$4,923,711in general payments, 2019–2025

Across 2,038 payments — averaging $2415.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • UCB SA$736K
  • Regeneron$477K
  • Novartis$453K
  • AbbVie$379K
  • Amgen$331K
  • plus $1.4M from 51 others
$82,843in research payments, 2019–2025

Across 44 payments — averaging $1882.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$31K
  • Eli Lilly$25K
  • Regeneron$13K
  • Sanofi US Services Inc.$9K
  • UCB, Inc.$5K

What the payments were for

  • Consulting fees$139,89723%
  • Speaking & faculty fees$412,32266%
  • Travel & lodging$38,7226%
  • Food & beverage$28,5605%
  • Education$8770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly126$1,145,612
UCB SA27$735,955
Regeneron196$477,274
Novartis105$452,910
AbbVie(2 entities)249$379,302
Amgen38$330,591
Incyte Corporation113$181,119
UCB, Inc.174$164,743
Takeda Pharmaceuticals U.S.A., Inc.20$161,737
Janssen Research & Development, LLC13$152,093
Regeneron Healthcare Solutions, Inc.148$147,670
Sanofi93$124,024
Sanofi US Services Inc.16$109,723
E.r. Squibb & Sons, L.L.C.56$98,203
Pfizer74$79,073
Boehringer Ingelheim25$60,483
Lilly USA, LLC123$44,771
LEO Pharma AS6$22,397
Boehringer Ingelheim Pharma GmbH & Co.kg25$8,998
Boehringer Ingelheim International GmbH8$8,893
Arcutis Biotherapeutics, Inc.30$7,091
Janssen Global Services, LLC5$5,650
Merck2$3,445
Bristol Myers Squibb(2 entities)5$3,405
Dermavant Sciences, Inc.27$3,140
Dermira, Inc.1$3,025
Galderma Laboratories, L.p.27$2,148
Almirall LLC6$1,858
Johnson & Johnson94$1,693
Insmed, Inc.7$1,151
Janssen Scientific Affairs, LLC3$1,028
Ortho Dermatologics, A Division Of Bausch Health US, LLC45$822
Sun Pharmaceutical Industries Inc.30$764
LEO Pharma Inc.33$661
UCB Biosciences Inc.12$530
Sanofi-aventis U.S. LLC12$336
Mayne Pharma Commercial LLC14$218
Octapharma USA, Inc.6$206
Hydrofera LLC3$123
Mallinckrodt Hospital Products Inc.5$123
Botanix SB Inc5$111
Paratek Pharmaceuticals, Inc.5$111
Helsinn Therapeutics (U.S.), Inc.5$95
Biocon Biologics Inc3$70
Sandoz2$42
Krystal Biotech Inc2$35
Organon2$31
Springworks Therapeutics, Inc.1$31
Blueprint Medicines Corporation1$30
Strata Skin Sciences, Inc.3$28
Eli Lilly Export S.A. Puerto Rico Branch1$27
Kyowa Kirin, Inc.1$25
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$22
Verrica Pharmaceuticals Inc.1$21
BD1$15
LNHC, Inc1$14
Alk-abello, Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,923,711 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$331,605
Medicare patients
1,043
Services billed
5,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5025$332,861
Skyrizi PenRisankizumab-Rzaa15$309,869
Humira(Cf) PenAdalimumab21$284,819
Dupixent SyringeDupilumab67$258,630
Bimzelx AutoinjectorBimekizumab-Bkzx15$219,812
Dupixent PenDupilumab49$195,814
RemicadeInfliximab17$181,497
Gamunex-CImmune Globul G/Gly/Iga Avg 4622$120,451
Taltz SyringeIxekizumab12$81,657
RinvoqUpadacitinib12$73,071
Mycophenolate Mofetil39$10,314
Clobetasol Propionate195$8,818
Acitretin23$4,978
Tacrolimus25$3,223
Betamethasone Dipropionate73$2,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$79,073$332,86125 claims
Johnson & JohnsonRemicade$1,693$181,49717 claims
AbbVieRinvoq$379,302$73,07112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.

Other dermatology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →